EA200801399A1 - Замещённые 5-гетероарил-1-фенилпиразольные каннабиноидные модуляторы - Google Patents

Замещённые 5-гетероарил-1-фенилпиразольные каннабиноидные модуляторы

Info

Publication number
EA200801399A1
EA200801399A1 EA200801399A EA200801399A EA200801399A1 EA 200801399 A1 EA200801399 A1 EA 200801399A1 EA 200801399 A EA200801399 A EA 200801399A EA 200801399 A EA200801399 A EA 200801399A EA 200801399 A1 EA200801399 A1 EA 200801399A1
Authority
EA
Eurasian Patent Office
Prior art keywords
phenylpyrazole
heteroaryl
substituted
cannabinoid
cannabinoid modulators
Prior art date
Application number
EA200801399A
Other languages
English (en)
Inventor
Миндэ Ся
Фина Лиотта
Менг Пан
Майкл П. Уочтер
Хуацзюнь Лу
Original Assignee
Янссен Фармацевтика, Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика, Н.В. filed Critical Янссен Фармацевтика, Н.В.
Publication of EA200801399A1 publication Critical patent/EA200801399A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение направлено на замещенный 5-гетероарил-1-фенилпиразольный каннабиноидный модулятор формулы (I) или его форму и способы применения при лечении, улучшении состояния или профилактике опосредованного каннабиноидным рецептором синдрома, расстройства или заболевания.
EA200801399A 2005-11-23 2006-11-17 Замещённые 5-гетероарил-1-фенилпиразольные каннабиноидные модуляторы EA200801399A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73912905P 2005-11-23 2005-11-23
PCT/US2006/044890 WO2007061948A2 (en) 2005-11-23 2006-11-17 Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators

Publications (1)

Publication Number Publication Date
EA200801399A1 true EA200801399A1 (ru) 2009-12-30

Family

ID=37983697

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801399A EA200801399A1 (ru) 2005-11-23 2006-11-17 Замещённые 5-гетероарил-1-фенилпиразольные каннабиноидные модуляторы

Country Status (16)

Country Link
US (1) US20070117858A1 (ru)
EP (1) EP1966194A2 (ru)
JP (1) JP2009517388A (ru)
KR (1) KR20080070078A (ru)
CN (1) CN101360741A (ru)
AU (1) AU2006318661A1 (ru)
BR (1) BRPI0618856A2 (ru)
CA (1) CA2630699A1 (ru)
CR (1) CR10111A (ru)
EA (1) EA200801399A1 (ru)
EC (1) ECSP088468A (ru)
IL (1) IL191585A0 (ru)
MX (1) MX2008006739A (ru)
NO (1) NO20082505L (ru)
WO (1) WO2007061948A2 (ru)
ZA (1) ZA200805405B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853205B2 (en) 2005-01-10 2014-10-07 University Of Connecticut Heteropyrrole analogs acting on cannabinoid receptors
WO2010104488A1 (en) * 2009-02-19 2010-09-16 University Of Connecticut Novel hetero pyrrole analogs acting on cannapinoid receptors
GB0625196D0 (en) * 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US10053444B2 (en) 2009-02-19 2018-08-21 University Of Connecticut Cannabinergic nitrate esters and related analogs
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
BR112019013493A2 (pt) * 2017-01-10 2020-01-07 National Health Research Institutes Compostos heterocíclicos e seus usos
CA3125847A1 (en) 2020-07-27 2022-01-27 Makscientific, Llc Process for making biologically active compounds and intermediates thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948718A (en) * 1960-08-09 New n-heterocyclic compounds
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
GR68380B (ru) * 1979-06-01 1981-12-28 Wellcome Found
LU83729A1 (fr) * 1981-11-04 1983-09-01 Galephar Sels d'acide valproique,leur preparation et leur utilisation
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5242940A (en) * 1987-05-29 1993-09-07 Ortho Pharmaceutical Corporation Pharmacologically active N-1 and C-5 heterocyclic pyrazoles and method for synthesizing the same
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
US20060025448A1 (en) * 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators

Also Published As

Publication number Publication date
CA2630699A1 (en) 2007-05-31
BRPI0618856A2 (pt) 2011-09-13
ZA200805405B (en) 2009-11-25
KR20080070078A (ko) 2008-07-29
MX2008006739A (es) 2009-03-04
EP1966194A2 (en) 2008-09-10
WO2007061948A2 (en) 2007-05-31
US20070117858A1 (en) 2007-05-24
AU2006318661A1 (en) 2007-05-31
JP2009517388A (ja) 2009-04-30
WO2007061948A3 (en) 2007-07-12
IL191585A0 (en) 2008-12-29
CN101360741A (zh) 2009-02-04
CR10111A (es) 2009-01-14
NO20082505L (no) 2008-08-12
ECSP088468A (es) 2008-06-30

Similar Documents

Publication Publication Date Title
EA200601760A1 (ru) Тетрагидроиндазольные модуляторы каннабиноидов
EA200800889A1 (ru) Гексагидроциклооктилпиразольные каннабиноидные модуляторы
EA200801399A1 (ru) Замещённые 5-гетероарил-1-фенилпиразольные каннабиноидные модуляторы
EA200800888A1 (ru) Модуляторы каннабиноидов на основе замещенных 3-амидотетрагидроиндазолилов
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA200700702A1 (ru) Аналоги локсапина и способы их применения
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
CY1111579T1 (el) Νεα συνδυασμενη χρηση μιας ενωσης σουλφοναμιδης (sulfonamide) στην θεραπεια του καρκινου
ATE550037T1 (de) Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen
RS52780B (en) MEANS OF PREVENTION AND TREATMENT OF DISORDERS CONCERNING MODULATION OF RYR RECEPTORS
EA200601912A1 (ru) Применение пептидных соединений для профилактики и лечения хронической головной боли
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
EA200601267A1 (ru) Модуляторы рецепторов андрогена
MX2010001714A (es) Moduladores de canabinoides 5-vinilfenil-1-fenil-pirazol sustituidos.
EA200800890A1 (ru) Модуляторы гексагидроциклогептапиразол каннабиноида
UA98487C2 (en) Hexahydro-cycloheptapyrazole cannabinoid modulators
EA200701584A1 (ru) Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения
EA200401032A1 (ru) Антиинфарктные молекулы
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren
CR9479A (es) Moduladores canabinoides de tetrahidrotiopirano pirazol
EA200600534A1 (ru) Сочетание ингибитора обратного захвата серотонина и амоксапина